We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

The US Food and Drug Administration (FDA) has expanded the approved use of Nubeqa (darolutamide) for patients with metastatic castration-sensitive prostate cancer (mCSPC). The drug is now approved for ...

Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.

Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.